Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04952545 · ClinicalTrials.gov registry record · Phase 1
Study of ALXN2050 in Healthy Adult Participants of Japanese Descent
A Phase 1 study, sponsored by Alexion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT04952545 is a Phase 1 study that has completed, run by Alexion Pharmaceuticals. The registered enrollment target is 20 participants.
The verdict
NCT04952545, a Phase 1 study, has completed, sponsored by Alexion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a Phase 1 bridging study being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALXN2050 after both single- and multiple-dosing in healthy participants of Japanese descent.
Interventions
- DRUG Placebo
- DRUG ALXN2050
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2021-07-09 |
| Est. Completion | 2021-09-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04952545
The ClinicalTrials.gov registry entry for NCT04952545 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04952545 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04952545 about?
NCT04952545 is a clinical study titled "Study of ALXN2050 in Healthy Adult Participants of Japanese Descent". This is a Phase 1 bridging study being conducted to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ALXN2050 after both single- and multiple-dosing in healthy participants of Japanese descent.
What is the current status of trial NCT04952545?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2021-07-09. Estimated completion is 2021-09-07.
What interventions are being tested in trial NCT04952545?
The interventions under investigation include: Placebo (DRUG), ALXN2050 (DRUG).
Who is sponsoring clinical trial NCT04952545?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.